The contribution of aberrant methylation alterations of BMP6, BRCA1 and P16 genes in lymph node metastasis might provide a further clue to establish useful biomarkers for screening metastasis, which might improve prognosis and therapeutic management of the breast cancer patients. This evidence concerns the gene BMP6 and metastatic malignant neoplasm in the lymph nodes.